WVE - uniQure: A High-Risk High-Reward Investment Opportunity
- uniQure has submitted data to the FDA that suggest that etranacogene dezaparvovec (AMT-061) is highly unlikely to be the cause of liver cancer in a patient in the pivotal trial.
- FTC review of the transaction with CSL Behring is ongoing and is projected to close during the second quarter of 2021.
- Wave Life Sciences and Roche/Ionis reported disappointing results in Huntington’s disease clinical trials.
- uniQure has made significant progress in their Huntington’s program and data readouts in late 2021 will give investors a glimpse into AMT-130’s efficacy and safety profile.
For further details see:
uniQure: A High-Risk, High-Reward Investment Opportunity